Our Pricing

BMI Requirements for Wegovy UK: Complete Eligibility Guide

Published on: June 03, 2026

Understanding the BMI requirements for Wegovy UK prescriptions is essential before starting treatment. At Cured Pharmacy, our UK-registered prescribers assess your eligibility based on MHRA-approved criteria: a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related health condition. Wegovy (semaglutide) is available from £79.00 following a free online consultation that takes under three minutes.

What Are the Official BMI Requirements for Wegovy in the UK?

Wegovy is licensed by the MHRA for adults with a body mass index (BMI) of 30 kg/m² or greater, classified as obesity [1]. Patients with a BMI of 27 kg/m² or above may also qualify if they have at least one weight-related comorbidity, such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease [1][2].

These criteria align with NICE guidance on pharmacological interventions for weight management and reflect the inclusion criteria used in the landmark STEP clinical trials [2]. During your consultation at Cured Pharmacy, our UK prescribers calculate your BMI and review your medical history to determine whether Wegovy is clinically appropriate for you.

It's important to note that BMI is just one part of the assessment. Prescribers also consider your previous weight loss attempts, current medications, contraindications, and overall health goals to ensure Wegovy is both safe and suitable for your individual circumstances.

How Is BMI Calculated for Wegovy Eligibility?

Body mass index is calculated by dividing your weight in kilograms by your height in metres squared (kg/m²). For example, if you weigh 90 kg and are 1.75 metres tall, your BMI is 90 ÷ (1.75 × 1.75) = 29.4 kg/m². This would fall into the overweight category, and you would need a documented weight-related condition to meet Wegovy eligibility criteria.

Our online consultation platform automatically calculates your BMI when you enter your height and weight. This ensures accuracy and allows our prescribers to make an informed decision quickly. If your BMI falls below the threshold, our clinical team may suggest alternative weight management strategies or medications that better suit your profile.

BMI Categories and Health Implications

The NHS classifies BMI into the following categories: underweight (below 18.5), healthy weight (18.5–24.9), overweight (25–29.9), obese class I (30–34.9), obese class II (35–39.9), and obese class III (40 or above). Wegovy is indicated for individuals in the obese categories or those in the overweight category with comorbidities [1].

While BMI is a useful screening tool, it doesn't account for muscle mass, bone density, or fat distribution. Our prescribers take a holistic view of your health, considering waist circumference, metabolic markers, and clinical history alongside BMI to assess your suitability for Wegovy treatment.

What Weight-Related Conditions Qualify You for Wegovy at Lower BMI?

If your BMI is between 27 and 29.9 kg/m², you may still qualify for Wegovy if you have at least one of the following conditions: type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol levels), obstructive sleep apnoea, or established cardiovascular disease [1][2].

These comorbidities significantly increase health risks associated with excess weight, and clinical trials have demonstrated that semaglutide can improve both weight and metabolic outcomes in this population [2][3]. During your consultation, you'll be asked to disclose any diagnosed conditions and current medications so our prescribers can verify eligibility.

Patients with type 2 diabetes, in particular, may benefit from Wegovy's dual action on weight and glycaemic control. In the STEP 2 trial, participants with type 2 diabetes lost an average of 9.6% of their body weight over 68 weeks, alongside improvements in HbA1c levels [3].

Documentation and Medical History

You may be asked to provide evidence of your weight-related condition, such as recent blood pressure readings, HbA1c results, or a letter from your GP. This helps our prescribers ensure that Wegovy is prescribed safely and in line with MHRA and NICE guidelines.

If you're unsure whether your condition qualifies, our clinical team at Cured Pharmacy can review your medical history during the consultation and provide clear guidance on your eligibility and alternative options if Wegovy isn't suitable.

Clinical Evidence: Wegovy's Efficacy Across BMI Categories

The STEP clinical trial programme evaluated semaglutide 2.4 mg (Wegovy) in over 4,500 adults with obesity or overweight plus comorbidities. In STEP 1, participants without diabetes achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo [2].

STEP 2 focused on individuals with type 2 diabetes and a BMI ≥27 kg/m². These participants lost an average of 9.6% of their body weight, demonstrating that Wegovy is effective across different BMI ranges and metabolic profiles [3]. Importantly, weight loss was accompanied by improvements in cardiovascular risk factors, including blood pressure, lipid profiles, and inflammatory markers [2][3].

Real-world data from UK clinics mirrors these trial outcomes, with patients reporting sustained weight loss and improved quality of life when Wegovy is combined with dietary modification and increased physical activity. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), emphasises that medication is most effective when integrated into a comprehensive lifestyle programme.

What Happens If Your BMI Is Below the Threshold?

If your BMI is below 27 kg/m² and you have no qualifying comorbidities, Wegovy is not clinically indicated and our prescribers will not approve the prescription. This is in line with MHRA licensing and patient safety protocols.

In such cases, our clinical team may recommend evidence-based alternatives, such as structured dietary plans, behavioural support, or other pharmacological options if appropriate. We prioritise safe, responsible prescribing and will always guide you towards the most suitable intervention for your health profile.

It's also worth noting that if you're close to the threshold, small changes in weight or the identification of a previously undiagnosed condition (such as prediabetes or hypertension) may alter your eligibility. Our team can provide advice on next steps and re-assessment timelines if needed.

Alternative Weight Management Options

For patients who don't meet Wegovy's BMI requirements, other treatments may be more appropriate. These include lifestyle interventions, NHS-approved weight management programmes, or medications with different eligibility criteria.

At Cured Pharmacy, we're committed to supporting your health journey, whether that involves Wegovy or another pathway. Our consultations are designed to provide personalised, evidence-based guidance tailored to your individual circumstances.

How to Start Your Wegovy Assessment at Cured Pharmacy

Starting your Wegovy journey is straightforward. Complete our free online consultation, which takes under three minutes and includes questions about your height, weight, medical history, current medications, and weight loss goals. Our UK-registered prescribers review every submission individually, ensuring your safety and suitability.

If approved, your prescription is processed and dispensed by our GPhC-registered pharmacy (9012511). Wegovy is delivered in discreet packaging directly to your door, with tracking provided. Prices start from £79.00, and you'll see the full cost before completing your consultation—no hidden fees or surprise charges.

Ongoing support is available throughout your treatment. Our clinical team can adjust dosing schedules, address side effects, and provide guidance on diet and exercise to optimise your results. We're here to support you every step of the way, from eligibility assessment to long-term weight maintenance.

What to Expect During Your Consultation

Your consultation will ask for details including your current weight, height, any diagnosed health conditions, medications you're taking, and previous weight loss attempts. This information allows our prescribers to calculate your BMI, assess comorbidities, and determine whether Wegovy meets MHRA prescribing criteria for your case.

Most consultations are reviewed within 24 hours. If additional information is needed, our team will contact you promptly. Once approved, your medication is dispatched quickly, often arriving within 1-2 working days depending on your location.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics. GOV.UK. https://www.gov.uk/ [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.